Afatinib is an ErbB-family blocker that is approved for use in patients with NSCLC [19, 20]; it irreversibly binds to and blocks EGFR (ErbB1), HER2 (ErbB2), and ErbB4. Here, ERBB2 is linked to non-small cell lung carcinoma.